Notice concerning release date for the NeuroSearch financial statements 2007

Announcement                                                                    





--------------------------------------------------------------------------------
| Notice concerning release date for the NeuroSearch financial statements 2007 |
--------------------------------------------------------------------------------
| The NeuroSearch A/S (NEUR.CO) annual report 2006 will be on the agenda of    |
| the board meeting scheduled for 5 March 2007 and the financial statements    |
| will be released on the same day.                                            |
| A teleconference will be held on 5 March 2007 at 3 pm Copenhagen time (2 pm  |
| London time, 9 am New York time). Flemming Pedersen, CEO, Anita Milland,     |
| Vice President, CFO and Hanne Leth Hillman, Vice President, Director of IR & |
| Corporate Communications, will present the annual report and answer          |
| questions. The telephone conference will be conducted in English and the     |
| telephone number is +44 (0)20 7162 0125. The corresponding PowerPoint        |
| presentation will be available via www.neurosearch.com.                      |
--------------------------------------------------------------------------------
| Asger Aamund                                                                 |
| Chairman of the Board                                                        |
--------------------------------------------------------------------------------
| Contact person: | Hanne Leth Hillman, Vice President,                        |
|                 | Director of IR & Corporate Communications                  |
--------------------------------------------------------------------------------
| Telephone:      | +45 4460 8212 or +45 4017 5103                             |
--------------------------------------------------------------------------------
| StockWise summary:                                                           |
| The NeuroSearch annual report 2006 will be on the agenda of the board        |
| meeting scheduled for 5 March 2007. The financial statements will be         |
| released on the same day and a teleconference will be held at 3 pm           |
| Copenhagen time (2 pm London time, 9 am New York time).                      |
| NeuroSearch is a Scandinavian biopharmaceutical company listed on the        |
| Copenhagen Stock Exchange (NEUR). Our core business covers the development   |
| of novel drugs, based on a broad and well-established drug discovery         |
| platform focusing on ion channels and transporters. A substantial part of    |
| the company's activities are partner financed through a broad alliance with  |
| GlaxoSmithKline (GSK) and collaborations with among others Abbott and        |
| Astellas. Eight drug programmes are in clinical development: ACR16 for the   |
| treatment of Huntington's disease (under preparation for Phase III),         |
| tesofensine for the treatment of obesity/type 2 diabetes (Phase II), NS2359  |
| for the treatment of depression (Phase II) and ADHD (Phase II) in            |
| partnership with GSK, NS1209 for the treatment of epilepsy and pain (Phase   |
| II), ABT-894 for pain treatment (Phase I) in partnership with Abbott, ACR16  |
| for the treatment of schizophrenia (Phase I) in partnership with Astellas,   |
| and ACR325 for the treatment of psychoses such as bipolar disorder (Phase    |
| I). In addition, NeuroSearch has a broad portfolio of preclinical drug       |
| candidates and has equity interests in several biotech companies.            |
--------------------------------------------------------------------------------